Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6

Xiaohong Wang  
*National Institutes of Health*

Hsukun Wang  
*University of Alabama - Birmingham*

John P. McCoy  
*National Institutes of Health*

Nilam Sanjib Banerjee  
*University of Alabama - Birmingham*

Janet S. Rader  
*Washington University School of Medicine in St. Louis*

See next page for additional authors

Follow this and additional works at: [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

Recommended Citation

Wang, Xiaohong; Wang, Hsukun; McCoy, John P.; Banerjee, Nilam Sanjib; Rader, Janet S.; Broker, Thomas R.; Meyers, Craig A.; Chow, Louise; and Zheng, Zhiming, "Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6." *RNA*. 15,4. 637-647. (2009). [https://digitalcommons.wustl.edu/open_access_pubs/4165](https://digitalcommons.wustl.edu/open_access_pubs/4165)

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncprotein E6

XIAOHONG WANG,1 HSU-KUN WANG,2 J. PHILIP MCOOY,3 NILAM S. BANERJEE,2 JANET S. RADER,4 THOMAS R. BROKER,2 CRAIG MEYERS,5 LOUISE T. CHOW,2 and ZHI-MING ZHENG1

1HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
2Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
3Flow Cytometry Core, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
4Department of Gynecology, Washington University School of Medicine, St. Louis, Missouri 63110, USA
5Department of Microbiology and Immunology, Penn State University College of Medicine, Hershey, Pennsylvania 17033, USA

ABSTRACT

MicroRNAs (miRNA) play pivotal roles in controlling cell proliferation and differentiation. Aberrant miRNA expression in human is becoming recognized as a new molecular mechanism of carcinogenesis. However, the causes for alterations in miRNA expression remain largely unknown. Infection with oncogenic human papillomavirus types 16 (HPV16) and 18 (HPV18) can lead to cervical and other ano-genital cancers. Here, we have demonstrated that cervical cancer tissues and cervical cancer-derived cell lines containing oncogenic HPVs display reduced expression of tumor-suppressive miR-34a. The reduction of miR-34a expression in organotypic tissues derived from HPV-containing primary human keratinocytes correlates with the early productive phase and is attributed to the expression of viral E6, which destabilizes the tumor suppressor p53, a known miR-34a transactivator. Knockdown of viral E6 expression in HPV16+ and HPV18+ cervical cancer cell lines by siRNAs leads to an increased expression of p53 and miR-34a and accumulation of miR-34a in G0/G1 phase cells. Ectopic expression of miR-34a in HPV18+ HeLa cells and HPV+C0 HCT116 cells results in a substantial induction of cell growth retardation and a moderate cell apoptosis. Together, this is the first time a viral oncprotein has been shown to regulate cellular miRNA expression. Our data have provided new insights into mechanisms by which high-risk HPVs contribute to the development of cervical cancer.

Keywords: miR-34a; p53; human papillomavirus; E6; oncprotein

INTRODUCTION

Human papillomavirus type 16 (HPV16) or 18 (HPV18) infection is widely recognized as a leading cause of cervical, penile, and anal cancers. Two viral oncoproteins, E6 and E7, of HPV16 and HPV18 are responsible for viral oncogenesis by destabilizing two major cellular tumor suppressors, p53 and pRb, respectively (Scheffner et al. 1990; Gonzalez et al. 2001). Tumor suppressor protein p53 functions as a transcription factor in regulating the transcription of many hundreds of protein-coding genes to safeguard the integrity of the genome by inducing cell cycle arrest and DNA repair upon encountering DNA damage, or apoptosis if repair cannot be achieved (Mirza et al. 2003; Voutsen and Lane 2007; Halazonetis et al. 2008). The hypophosphorylated form of pRb binds to E2F family transcription factors and controls the G1-to-S transition of the cell cycle (Chellappan et al. 1992; Cobrinik 2005). Thus, destabilization of p53 and hypophosphorylated pRb by the two viral oncoproteins promotes excessive cell cycling and accumulation of mutations, leading to genome instability.

MiRNAs represent a new class of noncoding regulatory RNAs which are 21–25 nucleotides (nt) in length and modulate gene expression at the post-transcriptional level by base-pairing with complementary nucleotide sequences (seed matching) in the 5’ and 3’ untranslated regions (UTRs) of target miRNAs (Grimson et al. 2007; Lytle et al. 2007; Nielsen et al. 2007). Approximately 416 miRNA genes have now been identified in the human genome encoding ~340 distinct mature miRNAs, many of which are tissue-specific or temporally regulated in their expression (Landgraf

Reprint requests to: Zhi-Ming Zheng, HIV and AIDS Malignancy Branch, Center for Cancer Research, Room 6N106, 10 Center Drive, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; e-mail: zhengt@exchange.nih.gov; fax: (301) 480-8250.

Article published online ahead of print. Article and publication date are at http://www.rnajournal.org/cgi/doi/10.1261/rna.1442309.
et al. 2007). However, their biological functions and molecular targets remain largely undefined and experimentally untested. Deletions or mutations in miRNA genes, as well as aberrant expression of oncogenic or tumor-suppressive miRNAs, are common in human cancers (Calin and Croce 2006; Wang et al. 2008), but the causes for their aberrant expression are poorly understood. Although many human viruses produce their own viral miRNAs in the course of virus infection (Pfeffer et al. 2004, 2005; Cai et al. 2005; Samols et al. 2005; Tang et al. 2008; Umbach et al. 2008), there is no report on viral proteins in regulation of cellular miRNA expression.

Recently, miR-34a was identified as a direct transcriptional target of cellular transcription factor p53 (Chang et al. 2007; He et al. 2007; Raver-Shapira et al. 2007). This transactivation of miR-34a expression is triggered by the binding of p53 to a consensus p53 binding site identified in the miR-34a promoter region. Since HPV E6 oncoprotein destabilizes p53 during virus infection, one may assume a down-regulation of miR-34a expression in most cervical cancer tissues with oncogenic HPV infection. However, a direct correlation between down-regulation of miR-34a expression and p53 degradation by HPV oncoprotein E6 in cervical cancer has not been reported. In this study, we provide direct evidence that papillomaviral oncoprotein E6 expressed from HPV16 and HPV18 inhibits the expression of tumor-suppressive miR-34a by destabilization of p53, resulting in cell proliferation.

RESULTS

Reduction of miR-34a expression in cervical cancer and cervical cancer-derived cell lines

Our recent study demonstrated that cervical cancer exhibits aberrant expression of several oncogenic and tumor-suppressive miRNAs (Wang et al. 2008). To investigate whether oncogenic HPV infection could alter the expression of certain members of the miRNA family, we examined three pairs of age-matched normal cervix and cervical cancer tissues for the expression of tumor-suppressive miR-34a by Northern blotting. A profound reduction of miR-34a, which appeared as three separate bands differing by 1 nt and in the sizes of 22–24 nt, was detected in all three cervical cancer tissues, each with a high-risk HPV infection (Fig. 1A, B; Munoz et al. 2003). The heterogeneity of miR-34a in normal cervix and cervical cancer tissues was probably due to wobble digestion of the pre-miRNA by dicer as recently reported (Landgraf et al. 2007; Wang et al. 2008). The observed reduction of miR-34a in cervical cancer was further confirmed by another method, miRNA ligation assay (Maroney et al. 2007) from a pair of commercially obtained RNA samples derived from normal cervix and cervical cancer tissues (Fig. 1C, lanes 2, 3). Consistent with this finding, a remarkable reduction of miR-34a was found in all cervical cancer-derived cell lines containing integrated oncogenic HPV DNA (Fig. 1C, lanes 4–8) and an HPV-negative human keratinocyte line HaCaT (Fig. 1C, lane 10). There was no miR-34a production in an HPV-negative cervical cancer cell line C33A (Fig. 1C, lane 9). Both HaCaT and C33A cells contain a mutant p53 (Crook et al. 1991; Lehman et al. 1993).

High-risk HPV infection reduces miR-34a expression in host cells

To determine whether HPV infection causes a reduction of miR-34a prior to cancer development, human primary keratinocytes HVK from adult vaginal tissues or HFK from newborn foreskins were immortalized with oncogenic HPV16 or HPV18 genomic DNA and then grown as organotypic raft cultures on dermal equivalents consisting...
of collagen with embedded fibroblasts. Total RNA isolated from the raft cultures derived from control keratinocytes or HPV-immortalized keratinocytes was examined by Northern blot hybridization. A prominent reduction of miR-34a expression was observed in the raft cultures of the cells immortalized with HPV16 or HPV18 (Fig. 2). HVK, which produces much more miR-34a than HFK, appeared to be more sensitive than HFK for the reduction of miR-34a by high-risk HPV16 and HPV18 infection (Fig. 2A,B). Since cell immortalization by high-risk HPVs is a function of viral oncoproteins E6 and E7 (Munger et al. 2004), these data suggest a possible role of viral oncoproteins in the reduction of miR-34a expression.

We next examined the expression of miR-34a in the raft cultures prepared from HFKs containing HPV18 genomic plasmids without prior immortalization. In this approach, HFK from newborn foreskins was transfected with HPV18 genomic plasmids using Cre-mediated recombination and then put on raft culture for sample collection at days 8, 12, and 16. As shown in Figure 3A, HPV18-infected HFK raft cultures, when compared to noninfected ones, grew much faster with a thicker keratinocyte layer at all time points due to HPV18 infection-increased HFK proliferation and led to production of infectious viruses at day 12 and day 16 as indicated by the expression of the major viral capsid protein L1. Relative to control cultures, a notable reduction of miR-34a in 8-d-old HPV18-containing raft cultures prior to L1 expression could be observed despite RNA overloading as assessed by its U6 level (Fig. 3B, lane 4). After quantification and normalization to U6 loading, a greater than twofold reduction of miR-34a levels was obtained in the 8-d-old rafts with HPV18 infection (Fig. 3C). These results further imply that viral early proteins are directly involved in the down-regulation of miR-34a expression.

A functional p53 is important in the expression of miR-34a in cancer cells, but may be not fully responsible for miR-34a expression in the late stage raft cultures with acute HPV18 infection

As the expression of miR-34a is transactivated by p53 binding to a perfect p53 binding site in the miR-34a regulatory region (Chang et al. 2007; He et al. 2007; Raver-Shapira et al. 2007), we wish to investigate whether cellular p53 is directly involved in the expression of miR-34a in cervical cancer and cervical cancer-derived cell lines. The HPV-negative cervical cancer cell line, C33A, was chosen for the study because C33A is expressing a mutant form of p53 (Scheffner et al. 1991) and consequently no detectable miR-34a in a miRNA ligation assay (Fig. 1C), which is in contrast to HaCaT cells, an HPV-negative keratinocyte line. Although also expressing a mutant form of p53 (Lehman et al. 1993), the HaCaT cells do express miR-34a at a substantially reduced level (Fig. 1C). As shown in Figure 4A, both C33A and HPV16+ CaSki express a similar amount of miR-16 in Northern blot analyses, but C33A expresses no detectable miR-34a by Northern blotting (Fig. 4A, left panel). However, when wild-type p53 was ectopically expressed for 24 h in C33A cells by transient transfection, a substantial induction of miR-34a expression became prominent (Fig. 4A, right panel), indicating that the reduced indeed is related directly to destabilized or dysfunctional p53 in cervical cancer cells.

Although miR-34a expression can be transactivated by p53 in cervical cancer cells, an increased expression of miR-34a was found not fully associated with cellular p53 level in the late stage of HFK raft cultures with HPV18 infection. As shown in Figure 4B, a decreased expression of miR-34a was associated with a decreased level of p53 in the early stage (day 8) of HFK raft cultures with HPV18 infection. However, relative to the control raft cultures, miR-34a expression was restored in day 12 and day 16 HPV18 raft cultures (Fig. 4B) on or after capsid protein synthesis (Fig. 3A), when there was a high level of viral E7-mediated p21CIP1 and a further reduced expression of p53, implying...
the presence of a p53-independent pathway in the expression of miR-34a in this system.

**Expression of high-risk HPV oncoprotein E6 reduces miR-34a expression by destabilizing p53**

Since HPV E6 and E7 are two major viral early proteins produced in the early phase of viral infection and are expressed at elevated levels in cervical cancer and their derived cell lines (Munger et al. 2004; Tang et al. 2006b), we next investigated viral E6 expression in correlation with p53 and miR-34a production in HPV18+ HeLa cells and HPV16+ CaSki cells that express the wild-type p53. Through this study, we wish to provide a direct connection of viral E6 oncoprotein to p53 and miR-34a circuit in HPV infection. As shown in Figure 5, knocking down the expression of HPV18 E6 by an HPV18 E6-specific siRNA (Tang et al. 2006b) in HeLa cells stabilized p53 and induced the expression of p21<sup>cip1</sup>, a downstream target of p53 transcriptional activation (Fig. 5A,B). As expected, stabilization of p53 in HeLa cells by knocking down HPV18 E6 highly up-regulated miR-34a expression (Fig. 5C,D). Consistent with this observation, knocking down the expression of HPV16 E6 in CaSiKi cells by an HPV16 E6-specific siRNA also stabilized p53 (Tang et al. 2006b) and up-regulated the expression of miR-34a (Fig. 5E–G).

These observations were further verified in HFKs acutely transduced with HPV18 E6, E7, E6E7, or an empty control...
When HFKs acutely transduced with HPV18 E6 or E7 retrovirus, only the expression of E7 in HFK rafts induced S phase reentry in differentiated keratinocytes (Fig. 6A) and stabilization of p21cip1 (Fig. 6B, top panels). Collectively, these data indicate that the viral oncoprotein E6 is responsible for the observed down-regulation of miR-34a expression in oncogenic HPV-infected cells.

**Down-regulation of miR-34a expression in HPV-infected cells by viral E6 promotes cell proliferation**

To determine whether the E6-mediated down-regulation of miR-34a expression is important for the development of cervical cancer, we first demonstrated that the majority of miR-34a in HeLa cells treated with an E6-specific siRNA (Tang et al. 2006b), which stabilized p53 and up-regulated miR-34a (Fig. 5A–D), was found in G0/G1-phase cells upon cell sorting. There was a much higher miR-34a ratio (5.5-fold) of G0/G1 versus S/G2/M in E6 siRNA-treated cells than that in control siRNA-treated cells (Fig. 7A,B), consistent with p53 nuclear retention and its highest DNA binding and transactivation activity at the cell G1/S transition (Fogal et al. 2005). We next examined ectopic expression of miR-34a on HeLa cell growth. Because E7 destabilizes hypophosphorylated pRb in cervical cancer cells, E7-expressing cells lack an efficient checkpoint control in the G1 phase of the cell cycle and resist G1 growth arrest (Slebos et al. 1994; Jones and Munger 1997). Consistent with this, the ectopic expression of miR-34a in HeLa cells had no effect on G1 phase, but led to a moderate cell cycle arrest at the S and G2/M phases and apoptosis (Fig. 8A,B). More importantly, there was a substantial growth retardation in HeLa cells with the ectopic expression of miR-34a (Fig. 8C,D). This suppressive effect on the cell growth was not an immediate cell response; rather, it took a few days to become prominent after two consecutive miR-34a transfections at an interval of 48 h (Fig. 8C). We infer from these results that cervical cancer cells with low miR-34a expression levels have a growth advantage. Moreover, these effects appear to be independent of the status of p53 and pRb, as in HPV-negative HCT116 cells, a cell line derived from colon cancer that contains wild-type p53 and increased pRb (Yamamoto et al. 1999) and thus has a functional G1 checkpoint, the
ectopic expression of miR-34a mediated a moderate cell cycle arrest at G1 and caused cell apoptosis and growth retardation (data not shown) in a dose-dependent manner. Similar to HeLa cell growth inhibition, this suppressive effect on HCT116 cell growth by miR-34a was found not to be an immediate cell response.

**DISCUSSION**

Although almost all human cancers examined to date display a certain level of aberrant miRNA expression or have mutant forms of miRNA, we know very little about their role in cancer or the cause leading to the aberrant expression. So far, there has been no report whether virus infection could regulate the expression of cellular miRNAs. In this study, we have demonstrated for the first time that miR-34a is down-regulated in productive, pre-malignant HPV infections, cervical cancer tissues, and cervical cancer cells (Figs. 1–3). This down-regulation can be attributed to the high-risk HPV E6 oncoprotein (Figs. 5,6), which mediates degradation of p53, a known regulator of miR-34a transcription (Chang et al. 2007; He et al. 2007; Raver-Shapira et al. 2007). This is the first compelling evidence to show a viral oncoprotein being involved in regulation of cellular tumor suppressive miRNAs. On the basis of these observations, we have added a new dimension to HPV-initiated carcinogenesis (Fig. 9). Viral oncoprotein E6 destabilizes p53 and consequently down-regulates the expression of tumor-suppressive miR-34a, providing the cells with a growth advantage. This untimely up-regulation of the viral oncoprotein E6, together with viral oncoprotein E7, which degrades pRB, can result in excessive cell proliferation, initiating the neoplastic and oncogenic processes. As low-risk HPV E6 does not degrade p53 (Tao et al. 2003), we presume that the low-risk E6 might have no effect on the expression of miR-34a.

Although miR-34a expression can be transactivated by p53 in this study and in several reports (Chang et al. 2007; He et al. 2007; Raver-Shapira et al. 2007), the expression of miR-34a might take place in a p53-independent manner under some particular conditions. The finding that miR-34a expression was restored in this report in day 12 and day 16 HPV18 raft cultures on or after capsid protein synthesis,

![Figure 6. Down-regulation of miR-34a expression by HPV18 E6 in HFK raft cultures. (A) S-phase re-entry by differentiated keratinocytes in raft cultures of HFKs transduced with HPV18 E6 or E7 retroviruses. BrdU incorporation was used to show E7-mediated S-phase re-entry. (B) Destabilization of p53 and reduction of miR-34a expression in raft cultures of HFKs acutely transduced with E6 or E6E7, but not by E7, retroviruses. Raft cultures with or without the corresponding retrovirus infection were harvested on day 10 for detection of p53 and p21 by (upper panel) Western (W) blotting or for total RNA preparation and (lower panel) Northern blotting. Tubulin served as protein sample loading in Western blotting. (C) Bar graph showing relative miR-34a levels detected by Northern blotting in B after being normalized to U6 for sample loading.](image)

![Figure 7. Accumulation of miR-34a in G0/G1-phase HeLa cells after transfection of E6-specific siRNA. (A) HeLa cells 48 h following treatment with or without an HPV18 E6-specific siRNA (Tang et al. 2006b) were sorted into G0/G1 and S/G2/M subpopulations by flow cytometry, and total RNA from each subpopulation was quantified for miR-34a expression by miRNA ligation analyses. (B) A ratio of miR-34a levels in the two subpopulations from each group was calculated after being normalized to tRNA for sample loading. One representative experiment of two is shown.](image)
when there was a further reduced expression of p53 and a high level of viral E7-mediated p21cip1, clearly suggests the presence of a p53-independent pathway in the expression of tumor suppressive miR-34a. We postulate that other transcription factors or chromatin remodeling in the differentiated HFKs must be involved in regulation of miR-34a transcription. A recent study shows that miR-34a expression can be inactivated by CpG methylation of its promoter (Lodygin et al. 2008).

The findings of miR-34a substantially accumulated in the G0/G1 phase and only a low level in the S/G2/M phase in E6 siRNA-treated HeLa cells suggest an elevated expression or stability of miR-34a in G0/G1-phase cells. This elevated steady-state miR-34a level in G0/G1-phase cells would contribute to an increased cell population arrested at the G1 phase when a functional G1 checkpoint is present in HPV-negative HCT116 cells (data not shown) or other cell lines (He et al. 2007; Tarasov et al. 2007). As nuclear retention and transactivation functions of Ser315-phosphorylated p53 are the highest at the G1/S transition and the Ser315 phosphorylation by increased cyclin A expression in the S phase could decrease p53 nuclear activities by promoting p53 nuclear export (Fogal et al. 2005), the elevated steady-state miR-34a level in G0/G1-phase cells observed in this study could be simply ascribed to this cell cycle-dependent nuclear retention and activities of Ser315-phosphorylated p53. Cell cycle-dependent changes in miRNA stability have been recently reported in HeLa cells, in which miR-29a and miR-30 were found to be constitutively expressed in all cell cycle phases, but miR-29b was expressed highly only in mitotic cells (Hwang et al. 2007). Thus, our data together with this report indicate a cell cycle-dependent regulation of miRNA expression and stability in controlling miRNA functions.

MiRNAs exercise large-scale effects on the expression of a variety of genes at the post-transcriptional level, and are estimated to regulate ~30% of mammalian genes. By prediction and experimental analyses, any given miRNA may have hundreds of gene targets (Brennecke et al. 2005; Farh et al. 2005; Lewis et al. 2005). In this study, we have demonstrated that cells with a reduced level of miR-34a expression have a growth advantage since the ectopic expression of miR-34a induces cell growth retardation and a moderate cell cycle arrest and apoptosis. As a moderate cell cycle arrest and apoptosis observed in this study might not fully cause a substantial cell growth retardation in the cells with the ectopic expression of miR-34a, the growth retardation mediated by miR-34a could be ascribed to many other unnoticed effects of miR-34a. For example, miR-34a has
been found to target multiple cell cycle components, including CDK4, cyclin E2, E2F-1, hepatocyte growth factor receptor MET, and Bcl-2 in other studies (Bommer et al. 2007; He et al. 2007; Tazawa et al. 2007; Welch et al. 2007). This multitargeting capacity by a single miRNA on cell cycling machinery may fine-tune a checkpoint for cell cycle progression. Recently, we also found that the ectopic expression of certain tumor-suppressive or oncogenic miRNAs affects cell doubling time (Wang et al. 2008). Thus, an efficient cell growth retardation mediated by miR-34a could result from a collection of many miR-34a–target interactions in spite of the fact that the exact mechanism by which miR-34a might function remains to be understood.

In summary, this is the first time that a viral oncoprotein has been shown to target cellular noncoding gene expression and the first report of regulative regulation of expression of a tumor suppressor miRNA. We have shown that at all stages of pathogenesis induced by the high-risk HPV types, the E6 destabilization of the tumor suppressor p53 down-regulates the tumor-suppressive miR-34a, leading to the elevated expression of cell cycle regulators and cell proliferation. These intimate interplays among viral E6, p53, miR-34a, and the tumor-suppressive miRNA. We have shown that at all stages of progression and the first report of viral regulation of expression of a certain tumor-suppressive or oncogenic miRNA affects cell doubling time (Wang et al. 2008). Thus, an efficient cell growth retardation mediated by miR-34a could result from a collection of many miR-34a–target interactions in spite of the fact that the exact mechanism by which miR-34a might function remains to be understood.

In summary, this is the first time that a viral oncoprotein—tumor suppressor network.

**MATERIALS AND METHODS**

**Cell lines and human tissues**

HPV16-positive cell lines CaSki and SiHa, HPV18-positive cell lines HeLa and C411, HPV68-positive cell line ME180 (Longuet et al. 1996), HPV-negative cervical cancer cell line C33A, and HPV-negative human keratinocyte line HaCaT cells (Stanley et al. 1989) were used in this study. All of these cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) with 10% FBS at 37°C and 5% CO2. HCT116 cells derived from colon cancer were grown in McCoy’s 5A medium with 10% FBS. Normal cervix and cervical cancer tissues were obtained from women with an age range from 40 to 50 yr old. HPV genotyping was done by sequencing-based techniques as previously described (Zhang et al. 2007). Use of these tissues was approved both by the Washington University Medical Center Human Studies Committee and by the NIH Office of Human Subjects Research. Each tissue was homogenized in an Eppendorf tube in 1 mL of TRizol Reagent (Invitrogen) using an electric homogenizer (Omini International) with a separate disposable probe. The isolated RNA was dissolved in RNase-free water and stored at −70°C.

**Northern blot analysis**

Total RNA (30–40 μg) was separated on a 15% denaturing polyacrylamide gel and transferred onto a GeneScreen Plus Hybridization Transfer Membrane (PerkinElmer) in 0.5× TBE buffer. The membrane was pre-hybridized with PerfectHyb Plus hybridization buffer (Sigma) for 2 h and then hybridized with [γ-32P]-labeled miRNA-specific antisense probe overnight at 40°C. The membrane was washed sequentially in 50 mL of 2× SSPE containing 0.5% SDS, 0.5× SSPE containing 0.5% SDS, and 0.2× SSPE containing 0.1% SDS for 30 min each at 40°C, and then exposed to a PhosphorImager screen. The image was captured using a Molecular Dynamics PhosphorImager Storm 860 and analyzed with ImageQuant software. The same membrane was stripped with 0.1× SSPE, 0.5% SDS for 20–30 min at 90°C and equilibrated with hybridization buffer for 2 h and then hybridized with the U6 snRNA probe. The antisense oligodeoxynucleotide probes were designed based on individual miRNA sequences deposited in miRBase (http://microrna.sanger.ac.uk). An antisense oligodeoxynucleotide (oST197, 5′-AAAATATGGACACGCTTCAAGGA-3′) was used to detect U6 snRNA from each sample as a loading control.

**miRNA ligation assay**

The miRNA ligation assay (Maroney et al. 2007) was performed using the miRtect-IT miRNA Labeling and Detection Kit (USB). In brief, detection oligo (oXHW66, 5′-CGCTTATGACATTC-3′) was 5′-end-labeled with [γ-32P]-ATP and OptiKinase. The miRNA in total RNA and the radiolabeled detection oligodeoxynucleotide were captured with miR-34a-specific bridge oligodeoxynucleotide (oXHW 79, 5′-GAATGTCTATAAGCG/ACAACCAGCTAAGACAGCGTCCCA-3′), and these were then ligated with T4 DNA ligase. The ligated miRNA was separated on a 15% denaturing polyacrylamide gel and exposed to a PhosphorImager screen for 2.5 h. The image was captured and analyzed as described above. After exposure, the gel was stained for tRNAs from each sample as a loading control with ethidium bromide (Yi et al. 2006). Depending on the designed bridge oligonucleotide, the miRNA ligation assay detects only one isoform of the interested miRNA.

**Western blot analysis**

Twenty-five microliters of cell protein lysates were denatured by boiling for 5 min and separated in a NuPAGE 4%–12% Bis-Tris gel (Invitrogen) in 1× NuPAGE MES SDS running buffer (Invitrogen). After transfer, the nitrocellulose membrane was blocked with 5% nonfat dry milk in Tris-buffered saline (TBS) (10 mM Tris, 150 mM NaCl at pH 7.4) for 1 h at room temperature. After a brief wash with...
TBS, the membrane was incubated overnight at 4°C with primary antibody. The membrane was washed three times with TTBS (TBS with Tween 20 at a final concentration of 0.05% [vol/vol]). Horseradish peroxidase-labeled secondary antibody (Sigma) diluted 10,000-fold in TTBS was incubated for 1 h at room temperature. After thorough washing, the immunoreactive proteins were detected with enhanced chemiluminescence using SuperSignal West Pico Western chemiluminescence substrate (Pierce). The signal was captured on X-ray film. The membrane was stripped and reprobed with another primary antibody. The primary monoclonal antibodies used were anti-p53 (Calbiochem; Ab-6; 1:100), anti-p21cip1 (BD Pharmingen; 6B6, 1:100), and anti-β-tubulin antibody (BD Pharmingen, 5H1, 1:1000).

**Cell transfection**

HeLa cells and HCT116 cells were transfected with 15 or 30 nM miR-34a Pre-miR Precursor (Ambion) or negative nonspecific control Pre-miR Precursor (Ambion) using siPORT NeoFX Transfection Agent (Ambion, Cat #4511) according to the manufacturer’s instructions. After 48 h, the cells were counted and transfected again with each corresponding miRNA with the same dose. After an additional 48 h, the cells were counted, and total RNA was extracted with TRIzol Reagent.

HPV-negative cervical cancer cells C33A at 5 × 10^5/mL in a 6-well plate were transfected with 4 μg/well of a wild-type p53 expression vector or an empty control vector using Lipofectamine 2000. Total RNA was prepared for Northern blotting 24 h after transfection.

**RNAi interference**

Ten, 50, or 100 nM synthetic double-stranded siRNA 219, which targets the HPV18 E6 coding region in intron 1 (nucleotides 353 to 371), or 40 nM synthetic double-stranded siRNA 209, which targets the HPV16 E6 coding region in intron 1 (nucleotides 277 to 298) (Tang et al. 2006b), were transfected into HeLa cells or CaSki cells, respectively, with siPORT NeoFX Transfection Agent (Ambion). Cells were seeded in triplicate in 6-well plates. Forty-eight hours post-transfection, total cell protein lysates were prepared by the addition of 2× sodium dodecyl sulfate (SDS) loading buffer, and total RNA was extracted with TRIzol Reagent (Invitrogen).

**Flow cytometry**

Apoptosis in HeLa or HCT116 cells was analyzed using Annexin V-FITC Apoptosis Detection Kit II (BD Pharmingen). Cells were trypsinized, washed twice with cold PBS, and then resuspended in 1× binding buffer at 1 × 10^6 cells/mL. Five microliters of annexin V-FITC and 5 μL of propidium iodide (PI) were added to 100 μL of cells (1 × 10^5 cells) in a 5-μL culture tube and incubated for 15 min at room temperature in the dark. After incubation, 400 μL of 1× binding buffer was added to each tube, and the samples were analyzed by flow cytometry within 1 h. For cell cycle analysis, the cells in suspension were stained with propidium iodide and analyzed by flow cytometry. For cell sorting and miR2 detection, HeLa cells at 2.3 × 10^5/mL were transfected with 10 nM siRNA 219 (HPV18 E6 siRNA) (Tang et al. 2006b) with siPORT NeoFX Transfection Agent (Ambion). After 48 h of incubation, cells were trypsinized, resuspended in serum-free medium at 3 × 10^6 cells/mL, and stained with 15 μg/mL Hoechst 33342 (Invitrogen) for 1.5 h at 37°C. After pelleting by a brief centrifugation, the cells were resuspended in 500 μL of serum-free medium and subjected to cell sorting by flow cytometry. Total RNA from the sorted cells was extracted with TRIzol Reagent for miRNA detection.

**Primary human keratinocytes, retrovirus infection, and organotypic cultures**

Primary human foreskin keratinocytes (HFKs) and human vaginal keratinocytes (HVks) were cultured in KSFm (Invitrogen) as described previously (Dollard et al. 1992; Meyers et al. 1992) and immortalized by HPV16 or HPV18 genomic DNA. Raft cultures were prepared as described (McLaughlin-Drubin and Meyers 2005). The method to generate HPV18 genomic plasmids using Cre-mediated recombination in transfected HFKs, without immortalization as well as the production of infectious HPV18 progeny viruses in raft cultures, has been described elsewhere (Wang et al. 2009).

The empty retroviral vector pLC and the pLJ HPV18 URR E6/E7 have been described previously (Cheng et al. 1995). The viral oncogenes are under the control of the homologous 1-kb contiguous upstream regulatory region (URR) containing transcription enhancers and the E6 promoter. The pLC-18URR-LLE7 has a URR in control of the expression of the HPV18 E7 gene with a long 5′ UTR derived from a truncated E6 gene (Genovese et al. 2008). The pLJ-18URR-E6 was derived from pLJ-18URR-E6E7 by removing the HPV18 sequences downstream from E6 between flanking NsiI sites. Amphotrophic recombinant retroviruses were prepared from GP+envAM12 (ATCC). Infected HFKs were selected with 250 μg/mL G418 for 2 d and then develop into organotypic cultures as previously described (Wilson et al. 1992; Cheng et al. 1995; Banerjee et al. 2005). The medium was supplemented with 50 μg/mL BrdU for 12 h immediately before harvest on day 10 to mark cells in S phase. The raft cultures were collected free from collagen (no fibroblasts) at specified time points and frozen in dry ice for total RNA and/or protein preparation or were formalin-fixed and paraffin-embedded for in situ analysis.

**Immunohistochemistry and microscopy**

Four-micrometer sections of raft culture were deparaffinized and stained with hematoxylin and eosin or subjected to immunohistochemistry. BrdU was detected with the mouse anti-BrdU antibody (1:100 dilution; Calbiochem) followed by Alexa 555-conjugated goat anti-mouse antibody (1:200 dilution; Invitrogen/Molecular Probes). Images were acquired with an Olympus AX70 fluorescence microscope with Speicher filters (Chroma) and a Carl Zeiss Axiocam HR digital camera. The HPV18 L1 major capsid protein was detected with a monoclonal primary antibody K1H8 (1:100; DakoCytomation Inc.) and reacted with Concentrated Detection System (BioGenex) and DAB kit (Innovex Biosciences). The sections were counterstained with hematoxylin and mounted with Permount. Images were captured with an Olympus BH2 microscope using a SPOT camera (Diagnostic Instruments).

**ACKNOWLEDGMENTS**

We thank John Brady at the National Cancer Institute for the p53 expression vector. This work was supported by the Intramural
Research Program of the National Institutes of Health, the National Cancer Institute, and the Center for Cancer Research and National Heart, Lung, and Blood Institute. This work also was supported partially by grants from the U.S. National Institutes of Health: Grant Nos. CA095713 (to J.S.R.), AI057988 (to C.M.), and CA083679 (to L.T.C.).

Received November 1, 2008; accepted December 22, 2008.

REFERENCES


